About US
Contact us
-
Under pressure, Brennan bows out as AstraZeneca CEOThe David Brennan era at AstraZeneca ($AZN) is over. The company's board, pressured by restless investors, asked Brennan to bow out yesterday, BBC News reports. The board also invited Chairman Louis S2012/4/28
-
Pfizer, Roche, GSK said to be knocking heads with generics on EU drug trackingA proposal by the European Union to require unique identifiers on drug packages to fight counterfeiting has sparked a fight between branded makers that say OK and generics companies that claim that it2012/4/28
-
Rumors put Bayer, Onyx at the M&A altarWith the Watson Pharmaceuticals-Actavis deal wrapped up, M&A hounds need something new to sniff out. And voilá! Reuters sources come through with a putative multibillion-euro Bayer Healthcare deal2012/4/27
-
SFDA further defines time limits for ophthalmic preparations to meet the requirements of newly revised GMPThe State Food and Drug Administration (SFDA) recently issued a notice to further define time limits for ophthalmic preparations and related products to meet the requirements of newly revised GMP.In a2012/4/27
-
Conflict threatens as FDA user-fee bills near a voteFDA user-fee legislation may be in the home stretch, but some proposals could slow it down as it nears the finish line. As Politico reports, amendments tagged onto user-fee bills promise to drag ou2012/4/26
-
GSK scrapes up 2% sales growth despite politics, genericsEurope is once again a big drag on pharma earnings. For GlaxoSmithKline ($GSK), the European ball and chain slowed drug and vaccine sales6%. Good thing U.S. revenues took a 9% leap--and emerging ma2012/4/26
-
Diovan rivals, plant woes pinch Novartis profitsNovartis ($NVS) results got squeezed by Diovan generics on one flank and a plant slowdown on the other. Diovan sales dropped15% as European generics continued to erode market share. And consumer healt2012/4/25
-
Pradaxa hits blockbuster mark, swelling Boehringer salesBoehringer Ingelheim is riding a sales surge. The German company expects "high single digit" growth in revenues for 2012 and another leap in 2013. That's after 2011 sales came in 5% higher, at €13.2 b2012/4/25
-
FDA warns 56 more docs of fake Avastin suppliesThe FDA has traced 56 more doctors and medical practices that may have bought phony versions of Avastin. As TheWall Street Journal reports, the agency notified the physicians and clinics in 13 states2012/4/24
-
China sweeps up dozens in whirlwind drug-capsule probeChinese police are all over the chromium-tainted drug capsules. They've detained 45 people, arrested 9 people and seized 77 million contaminated capsules, Reuters reports. Eighty illegal production2012/4/24